Belsomra vs Trazodone Side Effects: Which Sleep Medicine Is Better for Women?

Why Women Need a Separate Conversation About Sleep Medications

Women are about 40 percent more likely than men to report insomnia symptoms across their lifetime, according to data from the NIH National Institute of Neurological Disorders and Stroke. That gap widens at perimenopause. Choosing between suvorexant and trazodone is not just a question of which molecule works better on average. It is a question of which one fits your hormonal milieu, your life stage, your comorbidities, and your reproductive plans.

This article does not have a randomized head-to-head trial to cite, because none exists that directly compares suvorexant and trazodone in the same patient population. What we do have is strong Phase III data for suvorexant and a much thinner evidence base for trazodone's off-label sleep use, plus pharmacokinetic data that shows women process both drugs differently than men.

The Evidence Gap Is Real, and You Deserve to Know It

Women were historically excluded from sleep drug trials or enrolled in insufficient numbers to power sex-stratified analyses. The Herring et al. 2014 Lancet Neurology trial included women, but sex-specific efficacy subgroup data were not the primary endpoint. Trazodone's 2005 review by Mendelson in the Journal of Clinical Psychiatry acknowledged the paucity of rigorous RCT data supporting its widespread off-label use as a hypnotic. Both limitations matter when you are the one swallowing the pill.

How Each Drug Works: Mechanism Sets the Side-Effect Profile

Understanding the mechanism is the fastest shortcut to predicting which side effects you will face.

Suvorexant (Belsomra): Turning Off Wakefulness

Suvorexant is a dual orexin receptor antagonist. Orexin (also called hypocretin) is a neuropeptide that actively promotes wakefulness. Rather than sedating the brain with a broad depressant signal the way older hypnotics do, suvorexant blocks orexin-1 and orexin-2 receptors, effectively releasing the brain's natural brake on sleep. The Herring et al. Lancet Neurology 2014 trial, a Phase III randomized, double-blind, placebo-controlled study across 1,021 participants, showed statistically significant reductions in both subjective and objective wake after sleep onset at 15 mg and 30 mg doses (the approved therapeutic range is now 10 to 20 mg after FDA label revision).

Because suvorexant does not globally depress the CNS, it tends to preserve respiratory drive better than benzodiazepines. That matters for women with mild obstructive sleep apnea, a condition underdiagnosed in women because their symptoms often present as insomnia and fatigue rather than the textbook loud snoring seen in male patients.

Trazodone: An Antidepressant Repurposed for Sleep

Trazodone is not approved by the FDA for insomnia. Its sleep use is entirely off-label, resting on its histamine H1 and alpha-1 adrenergic antagonism at the low doses used for sleep (25 to 100 mg), distinct from its serotonin reuptake inhibition that dominates at antidepressant doses of 150 to 400 mg. The Mendelson 2005 review found that while trazodone improved subjective sleep in the short term, the controlled data were sparse and follow-up rarely exceeded two weeks. Long-term sleep efficacy data remain essentially absent.

Side-Effect Profiles, Compared Directly

No published randomized trial has put suvorexant and trazodone head-to-head in the same study. The comparison below synthesizes each drug's established adverse-event profile from their respective trial databases and pharmacovigilance records.

Daytime Drowsiness and Next-Day Impairment

Next-day somnolence is the most commonly reported side effect with suvorexant, occurring in approximately 7 percent of patients at 20 mg versus 3 percent on placebo in the Herring trial. Women metabolize suvorexant more slowly than men, largely because CYP3A4-mediated clearance is sex-dependent. The FDA label for suvorexant explicitly warns that women have approximately 17 percent higher plasma exposure than men at the same dose, meaning the 10 mg starting dose is particularly important for women to follow rather than self-escalate.

Trazodone's sedation at sleep doses (50 to 100 mg) is largely driven by H1 and alpha-1 blockade. Residual sedation the following morning is common and dose-dependent. Women with lower body weight, which is more prevalent on average in the female population, may experience more pronounced residual effects at equivalent doses.

Orthostatic Hypotension and Dizziness

Trazodone's alpha-1 blockade causes vasodilation. Orthostatic hypotension, the dizzy drop in blood pressure when you stand up, is a clinically meaningful risk. One cohort analysis published in JAMA Internal Medicine found trazodone among the sedating drugs associated with increased fall risk in older women. For perimenopausal and postmenopausal women who already experience vasomotor instability (hot flushes, autonomic fluctuation), adding an alpha-1 blocker amplifies that instability at night.

Suvorexant carries a much lower risk of orthostatic effects given its targeted orexin mechanism. Dizziness is listed as an adverse event in roughly 3 percent of suvorexant users in clinical trials, compared with rates of 5 to 10 percent for orthostasis-related symptoms with trazodone in older cohorts.

Complex Sleep Behaviors

Both drugs carry FDA boxed warnings or serious warnings related to complex sleep behaviors (sleep-driving, sleep-eating, sleepwalking with amnesia). Suvorexant received a formal FDA Drug Safety Communication in 2019 applying to the entire orexin antagonist class. Trazodone case reports of complex sleep behaviors exist in the literature but are less systematically characterized. Neither drug should be combined with alcohol or other CNS depressants.

Sexual Side Effects

This is a side-effect domain where women's concerns are frequently overlooked. Trazodone at antidepressant doses is associated with serotonergic sexual side effects including decreased libido and anorgasmia, though at the lower sleep doses (25 to 100 mg), the serotonin reuptake component is less dominant. Priapism is the most publicized sexual side effect, but it applies only to people with penises. What receives far less clinical attention is that trazodone may blunt genital arousal and orgasmic capacity in women through serotonergic pathways, particularly at doses creeping toward antidepressant range. No dedicated RCT has measured this outcome in women taking trazodone for sleep. Suvorexant does not carry a known signal for sexual dysfunction.

Weight and Metabolic Effects

Trazodone's H1 antagonism can stimulate appetite and contribute to weight gain, a side effect profile shared with antihistamines. For women with PCOS, who already carry elevated risk of insulin resistance and weight gain, this is a material consideration. Suvorexant does not have a meaningful metabolic or weight-gain signal in current trial data.

Anticholinergic Burden

Trazodone has modest anticholinergic activity that becomes more relevant as women age. The American Geriatrics Society Beers Criteria does not list trazodone as a high-risk anticholinergic, but cumulative anticholinergic load matters in midlife and older women, especially those already taking antihistamines, bladder medications, or certain antidepressants. Suvorexant does not have anticholinergic activity.

Women-Specific Physiology: How Hormones Change the Picture

Reproductive Years

During the menstrual cycle, sleep architecture shifts. Progesterone in the luteal phase has mild sedative properties via GABA-A receptor modulation, meaning you may need less pharmacological help in the second half of your cycle and more during the low-progesterone follicular phase. Neither drug's label accounts for this cyclical variation, but it is worth tracking your response across the cycle before deciding a dose is not working.

Women with PCOS have a higher prevalence of obstructive sleep apnea, estimated at 10 to 20 times the rate seen in women without PCOS, largely driven by androgen excess and higher BMI. Suvorexant's respiratory-sparing mechanism makes it a more cautious choice than trazodone (whose CNS sedation can blunt arousal responses) in women with suspected or confirmed sleep apnea.

Perimenopause and Menopause

The WomanRx Life-Stage Sleep-Drug Framework identifies three overlapping causes of perimenopausal insomnia that each drug addresses differently:

1. Hot-flush-triggered awakenings. Neither drug addresses the underlying vasomotor trigger. If nocturnal hot flushes are the primary driver, managing estrogen levels (via hormone therapy or non-hormonal options like fezolinetant) should come before or alongside sleep medication. A pill that helps you stay asleep does little if a flush wakes you every 90 minutes before the drug can work.

2. Mood-adjacent insomnia. Perimenopausal depression and anxiety are common and frequently co-present with insomnia. Trazodone's weak serotonergic action may offer a marginal mood co-benefit at higher sleep doses, though it is not a first-line antidepressant at 50 to 100 mg. Suvorexant has no psychotropic effect beyond sleep.

3. Pure sleep-architecture disruption. Women in late perimenopause and postmenopause show reduced slow-wave sleep and more fragmented REM. Suvorexant, by releasing the brain's natural sleep drive rather than imposing sedation, may preserve architecture better. Direct data in postmenopausal women comparing the two drugs do not exist, which is a gap worth naming.

The Menopause Society (formerly NAMS) 2023 position statement on nonhormonal management of menopause does not endorse either suvorexant or trazodone as a primary treatment for menopause-related sleep disturbance but acknowledges sleep disruption as a priority symptom when choosing therapy.

Thyroid Disease

Women with hypothyroidism, which affects roughly 5 percent of the U.S. Female population according to the American Thyroid Association, already carry fatigue and sedation burden. Adding trazodone in this group requires extra caution given overlapping sedation and potential for morning cognitive fog. Suvorexant's more targeted mechanism produces less additive daytime sedation in most patients, though thyroid-specific pharmacokinetic data for either drug are sparse.

Pregnancy and Lactation Safety

If you are pregnant or trying to conceive, discuss any sleep medication with your clinician before taking it. This section covers what the current evidence shows, not a recommendation to use either drug during pregnancy.

Suvorexant in Pregnancy and Lactation

Suvorexant has no adequate, well-controlled studies in pregnant women. Animal studies showed developmental toxicity at exposures well above the human therapeutic dose. Under the current FDA Pregnancy and Lactation Labeling Rule (PLLR), suvorexant carries a statement indicating risk cannot be ruled out. It is listed as Schedule IV controlled substance, which adds regulatory complexity during pregnancy management. Lactation data are absent. Suvorexant should be assumed to transfer into breast milk until data prove otherwise, and non-pharmacological sleep approaches are strongly preferred during breastfeeding.

Orexin plays a role in fetal neurodevelopment. While the clinical significance of maternal orexin receptor blockade on a developing fetus is not established, this mechanistic concern warrants conservatism.

Trazodone in Pregnancy and Lactation

Trazodone was classified as Pregnancy Category C under the old FDA system, meaning animal studies showed adverse effects and human data were inadequate. Observational human data are limited. Some registry studies have raised signals for neonatal withdrawal (jitteriness, feeding difficulty, respiratory distress) when serotonergic agents are taken in the third trimester, though trazodone-specific third-trimester data are thinner than for SSRIs. The ACOG practice bulletin on perinatal mental health does not include trazodone among preferred agents during pregnancy.

Trazodone does transfer into breast milk in small amounts. One pharmacokinetic study found infant relative dose estimates to be low, but data sets are small and infant exposure should be minimized where alternatives exist.

Contraception note: Neither suvorexant nor trazodone is a recognized teratogen requiring mandatory contraception in the way that isotretinoin or valproate does, but given the absence of safety data, reliable contraception while using either drug is a reasonable precaution for women who are not actively trying to conceive.

Who This Is Right For (and Who Should Think Twice)

Suvorexant May Be a Better Fit If You:

• Are postmenopausal and concerned about next-day cognitive effects from broader CNS sedation
• Have PCOS with suspected sleep apnea and need a respiratory-sparing agent
• Want an FDA-approved drug with Phase III RCT evidence behind it
• Have a history of falls or orthostatic hypotension and cannot afford an alpha-1 blocker's vasodilation
• Are concerned about weight gain or metabolic effects
• Have tried trazodone and experienced residual morning sedation

Trazodone May Be a Better Fit If You:

• Have comorbid low mood or anxiety alongside insomnia and your clinician has weighed the serotonergic benefit
• Need a low-cost, non-scheduled option (relevant if you have a history of substance use disorder, since suvorexant is Schedule IV)
• Have mild insomnia and respond well to gentle sedation at 25 to 50 mg without morning hangover
• Already take an SSRI and your prescriber has reviewed the serotonin syndrome risk and determined the combination is appropriate at the sleep dose

Neither Drug Alone Is Right If:

• Your insomnia is driven by hot flushes. Address estrogen or use fezolinetant first.
• You have untreated moderate-to-severe obstructive sleep apnea. Treat the apnea first.
• You are pregnant. Use cognitive behavioral therapy for insomnia (CBT-I) as the first-line approach; ACOG and the American Academy of Sleep Medicine both recognize CBT-I as the safest first-line option during pregnancy.

Switching Between Belsomra and Trazodone

Some women switch because one drug stops working, because side effects become intolerable, or because insurance changes the formulary. Here is what to know before you switch.

Trazodone is not physically habit-forming in the same way benzodiazepines are, but abrupt discontinuation after extended use can trigger rebound insomnia and, at higher antidepressant doses, discontinuation symptoms (dizziness, agitation, headache). If you have been taking trazodone at doses above 100 mg nightly for more than four weeks, taper rather than stop. At pure sleep doses (25 to 50 mg), discontinuation is generally better tolerated.

Suvorexant is Schedule IV, meaning physical dependence is possible, though the clinical literature describes its dependence profile as lower than traditional benzodiazepines or Z-drugs. Rebound insomnia on discontinuation has been reported in the first one to two nights. Cross-tapering directly from one drug to the other is clinically feasible but should be managed by your prescriber, not done unilaterally.

No published study has examined the optimal switching protocol from suvorexant to trazodone or vice versa, specifically in women. Your prescriber should weigh your hormonal status (estrogen levels influence CYP3A4 activity and therefore suvorexant clearance) when deciding whether the new dose needs adjustment.

Dosing Reference for Women

| Drug | Starting Dose for Women | Maximum Approved Sleep Dose | Notes for Women | |---|---|---|---| | Suvorexant (Belsomra) | 10 mg, 30 min before bed | 20 mg nightly | Women have ~17% higher exposure than men; do not self-escalate | | Trazodone (off-label) | 25 to 50 mg at bedtime | No FDA-approved sleep dose; clinical use typically <150 mg | Titrate slowly; orthostatic risk higher at doses above 100 mg |

Take suvorexant within 30 minutes of your intended sleep time and only when you have at least 7 hours remaining before you need to be alert. Take trazodone 30 to 60 minutes before bed on a full or partial stomach to reduce nausea.

Cost and Access

Generic trazodone is available at most pharmacies for under $15 per month for a 30-day supply at sleep doses. Suvorexant remains brand-only (Merck's Belsomra patent runs through the mid-2020s) and costs $300 to $400 per month without insurance. Many insurance plans require step therapy, meaning you must try and fail a cheaper agent (often trazodone, a Z-drug, or doxylamine) before suvorexant is covered. Manufacturer copay cards exist but do not apply to government insurance plans.